文献速递肾癌与肾肿瘤

机器人切除肾细胞癌肾切除后同侧腹膜后复发的可行性与安全性

Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma.
PubMed 文献 · Urology · 2020-08-21

该回顾性病例系列纳入2015-2018年12例肾细胞癌肾切除后同侧腹膜后复发患者,行机器人切除。平均年龄65.48岁,男性10例,平均BMI 34.75 kg/m2,复发灶平均大小2.97 cm。所有手术切缘阴性,无手术并发症。中位随访19.0个月,5例再次复发。结论认为在专家手中和精选患者中,机器人切除安全、技术可行且肿瘤学合理。

要点

  • 机器人切除肾细胞癌同侧腹膜后复发在精选患者中技术可行且安全。
  • 12例患者均实现切缘阴性且无手术并发症。
  • 中位随访19.0个月,5例再次复发,平均再复发时间26.5个月。

核心结论

  • 在专家手中和精心选择的患者中,机器人切除肾细胞癌同侧腹膜后复发似乎安全、技术可行且肿瘤学合理。

研究设计与样本

  • 回顾性病例系列,纳入2015-2018年12例肾细胞癌肾切除后同侧腹膜后复发行机器人切除的患者。
  • 平均年龄65.48岁(±SD 9.51),10例男性,平均BMI 34.75 kg/m2(±6.71)。
  • 9例根治性肾切除后复发,3例部分肾切除后复发;复发灶平均大小2.97 cm(±1.69)。

主要发现

  • 平均麻醉时间213分钟(±38.92),平均估计失血量152 mL(±130.75),平均住院时间43小时(±12.64)。
  • 所有手术切缘阴性,无手术并发症报告。
  • 中位随访19.0个月(IQR 12.7-30.0),12例中5例机器人切除后复发,接受全身治疗、放疗或姑息手术。
  • 后续复发平均时间26.5个月。

临床怎么用

  • 对于低负荷局部复发性肾细胞癌,机器人切除可作为开放手术的替代选择,可能延迟全身治疗的使用。

局限性

  • 小样本病例系列,结论需在专家手中和精选患者中解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine feasibility and safety of robotic excision of local ipsilateral recurrences after nephrectomy for renal cell carcinoma (RCC). Surgical resection is an option for treatment of low burden locally recurrent RCC, potentially delaying the use of systemic therapy. This has historically been performed by open technique, which can impart significant morbidity. We present our experience with robotic excision. METHODS: We reviewed our institutional experience of patients with surgically excised RCC who underwent robotic excision of ipsilateral retroperitoneal recurrence in 2015-2018. Demographics and clinicopathological variables, including operative and postoperative outcomes, were examined. RESULTS: Twelve robotic excisions of ipsilateral local recurrences were performed in our hospital in 2015-2018. Mean age was 65.48 years (± standard deviation, SD: 9.51), 10 patients were male, and mean BMI 34.75 kg/m2 (± 6.71). Nine patients recurred after radical nephrectomy, and 3 after partial nephrectomy. Mean size of recurrence was 2.97 cm (±1.69). Mean anesthesia time, EBL, and LOS were 213 minutes (± 38.92), 152 mL (± 130.75), and 43 hours (± 12.64), respectively. All surgical margins were negative. No surgical complications were reported. Median follow-up was 19.0 months [interquartile range, IQR 12.7-30.0]. Five patients out of 12 recurred following robotic excision, these were treated with either systemic therapy, radiation, or palliative surgeries. Mean time for subsequent recurrence was 26.5 months. CONCLUSION: In this small case series, robotic excision of ipsilateral RCC retroperitoneal recurrence appears safe, technically feasible, and oncologically sound in expert hands and carefully selected patients.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ghandour R, Miranda AF, Singla N, et al. Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma. Urology. 2020. PMID: 32828868. doi:10.1016/j.urology.2020.07.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。